CBIH: AI 评分 49/100 — AI 分析 (4月 2026)

Cannabis Bioscience International Holdings, Inc. focuses on providing educational systems related to medical cannabis and offering services in therapeutic areas such as clinical trials and sleep disorders. The company operates in the evolving medical cannabis sector, facing both opportunities and challenges in a competitive market.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Cannabis Bioscience International Holdings, Inc. (CBIH) operates in the medical cannabis education and therapeutic services sector, offering educational systems and clinical services. With a small team and a focus on online education and specialized treatments, CBIH navigates the competitive landscape of specialty drug manufacturers.

CBIH是做什么的？

Founded in 2003 and headquartered in Houston, Texas, Cannabis Bioscience International Holdings, Inc., formerly known as China Infrastructure Construction Corp., has evolved to focus on the medical cannabis industry. The company provides educational systems centered on medical cannabis in the United States, Latin America, and globally through online platforms. CBIH also offers services in therapeutic areas such as clinical trials and treatments for sleep disorders, including infertility resulting from these disorders, through its fertility and sleep center located in Houston. The company's offerings extend to education, consulting, digital publishing, marketing, and franchising related to medical cannabis through its Pharmacology University. CBIH operates with a small team, emphasizing specialized services within the burgeoning medical cannabis market.

CBIH的投资论点是什么？

Cannabis Bioscience International Holdings, Inc. presents a high-risk, high-reward investment profile within the volatile medical cannabis sector. With a market capitalization of $0.01 billion and a negative P/E ratio of -8.83, the company's financial performance indicates significant challenges. A gross margin of 28.5% is offset by a substantial negative profit margin of -465.3%, reflecting high operational costs relative to revenue. Growth catalysts include expanding its online educational platform and potential advancements in its therapeutic services. However, the company's small size, limited resources, and OTC market listing contribute to a higher risk profile. Investors should carefully consider the speculative nature of CBIH within the evolving cannabis industry.

CBIH在哪个行业运营？

Cannabis Bioscience International Holdings, Inc. operates within the rapidly evolving medical cannabis industry. This sector is characterized by increasing acceptance of cannabis for medical purposes, driving growth in related services such as education, clinical trials, and therapeutic treatments. The competitive landscape includes both established pharmaceutical companies and emerging cannabis-focused businesses. CBIH's focus on education and specialized treatments positions it within a niche segment, but it faces competition from larger players with greater resources and market reach. The industry is subject to changing regulations and market dynamics, requiring companies to adapt quickly to maintain competitiveness.

Drug Manufacturers - Specialty & Generic

Healthcare

CBIH有哪些增长机遇？

Expansion of Online Education Platform: CBIH can leverage the growing demand for medical cannabis education by expanding its online platform, Pharmacology University. This includes developing new courses, certifications, and partnerships with healthcare professionals. The global e-learning market is projected to reach $325 billion by 2025, providing a significant opportunity for CBIH to increase its revenue and market share. Timeline: Ongoing.
Development of Therapeutic Services: CBIH's fertility and sleep center in Houston offers specialized treatments for sleep disorders and related infertility. By investing in research and development, CBIH can expand its therapeutic offerings and attract more patients. The market for sleep disorder treatments is expected to reach $11.2 billion by 2027, presenting a substantial growth opportunity. Timeline: Ongoing.
Strategic Partnerships and Franchising: CBIH can pursue strategic partnerships with other companies in the medical cannabis industry to expand its reach and service offerings. Franchising its Pharmacology University can also generate additional revenue and brand awareness. The franchising market is estimated at over $750 billion globally, offering a scalable growth model. Timeline: 12-24 months.
Geographic Expansion: CBIH can expand its educational and therapeutic services to new geographic markets, particularly in Latin America, where the medical cannabis industry is growing rapidly. This includes establishing partnerships with local healthcare providers and adapting its offerings to meet local regulations and market needs. The Latin American cannabis market is projected to reach $8.5 billion by 2028. Timeline: 18-36 months.
Clinical Trials and Research: CBIH can conduct clinical trials and research to validate the efficacy of its therapeutic treatments and develop new products. This can enhance its credibility and attract funding from investors and research institutions. The global clinical trials market is expected to reach $68.9 billion by 2028, providing opportunities for CBIH to participate in research and development. Timeline: Ongoing.

Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
Negative P/E ratio of -8.83 reflects current unprofitability, suggesting the company is investing heavily in growth or facing operational challenges.
Gross margin of 28.5% shows the company's ability to generate revenue from its services, but needs improvement to achieve profitability.
Negative profit margin of -465.3% highlights significant operational inefficiencies or high expenses relative to revenue.
Beta of 1.94 indicates higher volatility compared to the market, reflecting the speculative nature of the medical cannabis industry.

CBIH提供哪些产品和服务？

Provides educational systems focused on medical cannabis.
Offers online education through Pharmacology University.
Provides services in therapeutic areas, including clinical trials.
Treats sleep disorders and related infertility.
Offers consulting services related to medical cannabis.
Engages in digital publishing and marketing related to medical cannabis.
Explores franchising opportunities for its educational programs.

CBIH如何赚钱？

Generates revenue through online education programs and courses.
Provides therapeutic services at its fertility and sleep center.
Offers consulting and marketing services to businesses in the medical cannabis industry.
Explores franchising opportunities to expand its educational reach.

Healthcare professionals seeking education and training in medical cannabis.
Patients seeking treatment for sleep disorders and related infertility.
Businesses in the medical cannabis industry seeking consulting and marketing services.
Individuals interested in learning about medical cannabis through online courses.

Specialized Focus: CBIH's focus on medical cannabis education and therapeutic services provides a niche market position.
Proprietary Content: Pharmacology University's curriculum and educational materials offer a unique value proposition.
First-Mover Advantage: Early entry into the medical cannabis education market provides a competitive edge.
Established Infrastructure: The fertility and sleep center in Houston provides a physical location for therapeutic services.

什么因素可能推动CBIH股价上涨？

Ongoing: Expansion of online education platform through Pharmacology University.
Ongoing: Development of new therapeutic services at the fertility and sleep center.
Upcoming: Potential strategic partnerships with other companies in the medical cannabis industry.
Upcoming: Geographic expansion into new markets, particularly in Latin America.
Ongoing: Clinical trials and research to validate the efficacy of therapeutic treatments.

CBIH的主要风险是什么？

Potential: Changing regulations and market dynamics in the medical cannabis industry.
Ongoing: Competition from larger companies with greater resources.
Potential: Negative publicity and reputational risks.
Ongoing: Economic downturns and reduced consumer spending.
Ongoing: Limited liquidity and high volatility due to OTC market listing.

CBIH的核心优势是什么？

Specialized focus on medical cannabis education and therapeutic services.
Online education platform provides global reach.
Established fertility and sleep center in Houston.
Early mover advantage in the medical cannabis education market.

CBIH的劣势是什么？

Small size and limited resources.
Negative profitability and high operational costs.
OTC market listing increases risk and reduces liquidity.
Dependence on the evolving medical cannabis industry.

CBIH有哪些机遇？

Expansion of online education platform and course offerings.
Development of new therapeutic services and treatments.
Strategic partnerships and franchising opportunities.
Geographic expansion into new markets, particularly in Latin America.

CBIH面临哪些威胁？

Changing regulations and market dynamics in the medical cannabis industry.
Competition from larger companies with greater resources.
Potential for negative publicity and reputational risks.
Economic downturns and reduced consumer spending.

CBIH的竞争对手是谁？

Australis Capital Inc — Focuses on cannabis investments and operations. — (AUSAF)
Ayr Wellness Inc — Operates cannabis cultivation and retail facilities. — (AYRWF)
BUDZ ETFMG Alternative Harvest ETF — An ETF focused on cannabis-related companies. — (BUDZ)
CV Sciences Inc — Develops and markets hemp-based CBD products. — (CVSI)
The Green Organic Dutchman Holdings Ltd — Focuses on organic cannabis cultivation and product development. — (DHBUF)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Dante Picazo
Headquarters: Houston, US
Employees: 2
Founded: 2023

AI Insight

AI analysis pending for CBIH

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cannabis Bioscience International Holdings, Inc. do?

Cannabis Bioscience International Holdings, Inc. operates in the medical cannabis sector, focusing on education and therapeutic services. The company provides educational systems through its Pharmacology University, offering online courses and training programs. Additionally, CBIH offers therapeutic services, including clinical trials and treatments for sleep disorders and related infertility, through its fertility and sleep center in Houston. The company aims to capitalize on the growing demand for medical cannabis education and specialized treatments, while navigating the challenges of the evolving industry.

What do analysts say about CBIH stock?

Given CBIH's micro-cap status and OTC listing, formal analyst coverage is unlikely. The company's financial metrics, including a negative P/E ratio and a negative profit margin, suggest significant challenges. Potential investors should focus on the company's growth initiatives, such as expanding its online education platform and developing its therapeutic services. However, the risks associated with OTC stocks and the evolving medical cannabis industry should be carefully considered. Independent research and due diligence are essential for evaluating CBIH's investment potential.

What are the main risks for CBIH?

Cannabis Bioscience International Holdings, Inc. faces several key risks, including regulatory uncertainty in the medical cannabis industry, competition from larger companies with greater resources, and potential negative publicity. The company's OTC market listing increases liquidity risk and volatility. Additionally, CBIH's financial performance, characterized by negative profitability and high operational costs, poses a significant challenge. Investors should carefully assess these risks and conduct thorough due diligence before considering an investment in CBIH.